| Abstrakt: |
A recent study conducted by researchers at the University of California focused on hyperplasia, a condition characterized by an increase in the number of cells in an organ or tissue. The study found that systemic immunostimulatory regimens, such as high dose IL-2 treatment for cancer, can induce thymic involution and reduce the production of naive T cells. However, the study also observed a rebound effect in which the thymus produced even more thymocytes after the initial involution. This rebound effect was not observed in aged recipients, leading to prolonged deficits in naive T cell numbers. The findings suggest that immunostimulatory therapies can have profound effects on thymic function and T cell output, particularly in older individuals. [Extracted from the article] |
